The future of biomedical research is animal-free

As a scientist focused on tangible data and results, it’s easy to be sceptical about the impact of legislative acts: the path from Congress to the lab is long and winding. Despite the subtle change and lack of immediate impact on patients, the FDA Modernization Act 2.0 is anything but inconsequential. I think, in truth, that it may be the spark needed to ignite the next era of animal-free drug…

Comments Off on The future of biomedical research is animal-free

Breast Cancer By A New Name: Redefining Disease For Better Patient Outcomes

Everyone knows someone with cancer, so this question may be confusing, but: Does anyone have cancer anymore? What I mean is: At first, there was cancer. Now, there is chronic myeloid leukemia and acute lymphocytic leukemia; primary colorectal lymphomas and gastrointestinal stromal tumors; and six subgroups of triple-negative breast cancer. We’ve outgrown the blanket term “cancer,” and it’s making a positive difference in how we treat and overcome disease. In…

Comments Off on Breast Cancer By A New Name: Redefining Disease For Better Patient Outcomes

The Problems We Must Overcome Before A Patient Enters Their Doctor’s Office

I had my first migraine in middle school. Over a decade later, I was prescribed a cocktail of drugs—my saving grace. I could finally take hold of my life, and I no longer held on to an ever-present worry that my migraines could steal days of my time and derail what I was working toward. I had an ideal experience: Diagnosis was possible, treatment was possible, and my response was…

Comments Off on The Problems We Must Overcome Before A Patient Enters Their Doctor’s Office

Q&A with Pepper Bio Senior Computational Biologist, Sam Roth

Please welcome the newest member of the Pepper Bio team, Sam Roth! Sam joins us from a role at Fulcrum Therapeutics, where he focused on developing computational methods for analyzing NGS data with the aim of target discovery in rare genetic disease. Sam’s first day at Pepper as a Senior Computational Biologist was just over a week ago. You can learn more about why Sam joined our team, as well…

Comments Off on Q&A with Pepper Bio Senior Computational Biologist, Sam Roth

Startup Pepper Bio Touts ‘Transomics’ as Key Strategy in its Drug Discovery Efforts

Reposted from Neil Versel, Editor at GenomeWeb CHICAGO – While multiomics seems to be a top biotech buzzword these days, drug discovery and bioinformatics startup Pepper Bio is trying to make a name for itself in the field of transomics. To that end, the Boston-based startup is leveraging support from Merck and other entities as part of an accelerator program to try and hone its strategy for applications such as…

Comments Off on Startup Pepper Bio Touts ‘Transomics’ as Key Strategy in its Drug Discovery Efforts

Ex-Phio VP, Simon Fricker, Joins Pepper Bio As Chief Development Officer

By Jon Hu, CEO and Cofounder of Pepper Bio  Pepper Bio, the world’s first transomics drug discovery company, announced the addition of Simon Fricker, Ph.D., as chief development officer. Previously, Dr. Fricker served three years as vice president of research and development at Phio Pharmaceuticals, a publicly-traded clinical-stage biotechnology company, and eight years as a distinguished scientific fellow at Genzyme/Sanofi. In his new role at Pepper, Dr. Fricker will support the…

Comments Off on Ex-Phio VP, Simon Fricker, Joins Pepper Bio As Chief Development Officer